Our smart devices combine dosing data with lab test information and consumer feedback to create a highly personalized experience that helps optimize itself.
RYAH empowers users through its seamless management of their dosing regimen with plant-based medicine. As a result, users can expect far more reliable results and an ever-improving experience.
We have worked diligently to keep your data anonymous while utilizing it to provide you with specialized recommendations to optimize your dosing experience.
If you’re curious to learn more about our dose-control products,
request a demo with one of our specialists.
RYAH’s easy-to-operate, portable devices provide countless advantages for you and your medical network. Our innovative technology aggregates session data, leaving you with more in-depth information about your dosing regimen and health needs. The data we gather opens new possibilities to obtain knowledge within the health industry.
Lightweight, mobile-controlled smart patch that can be boosted for on-demand dose control.
Dry herb inhaler with an integrated volumetric airflow sensor that enables consumers to easily track and control how much they inhale.
Multi-liquid chamber pen that accurately dispenses up to three different formulations at once for a dose-controlled entourage effect.
Cutting-edge software suite for medical professionals looking to improve the way they monitor and control their patients’ dosing regimen using RYAH’s smart products.
The goal of palliative care is to alleviate the suffering of patients with a chronic diagnosis. End-of-life care is not a curative approach but one
“RYAH Group Inc. Enters Italy and The Netherlands; Partners with THC Lab”
By leveraging our robust artificial intelligence platform which aggregates and correlates HIPAA-compliant dosing data from seed to consumption, RYAH generates in-depth analytical reports that can help identify trends and inform the medical community of how dosing is affecting consumer outcomes.
Whether you’re a doctor, researcher, product supplier, or investor, we’re ready to talk.
